Skip to main content

Table 2 Clinical and pathological data of patients included in miR-375 validation

From: MicroRNA-375 plays a dual role in prostate carcinogenesis

Clinicopathological data Tumors ( n= 114) MNPT ( n= 15)
Age (years), median (range) 65 (49 to 74) 64 (45 to 80)
PSA (ng/mL), median (range) 8.00 (2.66 to 20.00) n.a.
Pathological stage, n (%)
pT2 58 (38.7%) n.a.
pT3a 24 (16.0%) n.a.
pT3b 33 (21.3%) n.a.
Gleason score, n (%)
<7 28 (18.7%) n.a.
=7 73 (48.7%) n.a.
>7 13 (8.7%) n.a.
  1. n.a., not applicable; MNPT, morphological normal prostate.